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ABSTRACT 
 
Background: Vitamin D supplementation may benefit patients with active tuberculosis 
(TB) 
Design: A randomized, double-blinded, placebo-controlled clinical trial comparing 
standard active TB treatment to active TB treatment plus supplemental high dose oral 
vitamin D3 was performed in India. 
Methods: Treatment naïve, smear positive, HIV negative, pulmonary TB patients were 
randomized into two equal groups.   
Results: 247 patients were randomized, 121 to vitamin D and 126 to placebo.  Baseline 
characteristics in both groups were similar.  101 patients in the vitamin D arm and 110 
patients in the placebo arm were analyzed.   Median time to culture conversion in the 
vitamin D group was 43.0 days (95% C.I. = 33.3 to 52.8), as compared to was 42.0 days 
(33.9 to 50.1) in the placebo group (p=0.95 by log rank test).   Hypercalcemia was not 
observed.  
Conclusions: Vitamin D supplementation was safe but did not influence time to culture 
conversion. 
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Introduction 
 Tuberculosis (TB) is a disease recognized from antiquity, which continues to 
remain one of the most important infectious diseases in the world.  The World Health 
Organization annual TB report for 2012, containing data from 204 countries, summarized 
progress towards TB elimination.(1)  The global TB mortality rate has decreased 41% 
since 1990, and is on target to achieve the Millennium Development Goal of 50% 
reduction by 2015.  Access to TB care has increased significantly, collaborative 
approaches to TB and Human Immunodeficiency Virus (HIV) coinfection have been 
initiated, and new diagnostics have been developed.  Despite this evidence of progress, 
there were 8.7 million new cases of TB in 2011, with 1.4 million deaths.(1) 
 India continues to be the highest TB burden country in the world, with over 2 
million cases of active TB every year.(2) TB kills nearly 280,000 men, women and 
children annually and is one of the leading causes of death in India.  While the Revised 
National TB Control Program (RNTCP) has made progress, TB incidence continues to be 
high, and serious forms of drug-resistance have emerged, especially in urban hot spots.    
 TB is caused by Mycobacterium tuberculosis complex, a group of bacterial 
pathogens with a cell wall containing large amounts of mycolic acid, inhaled into the 
lung, which disseminate throughout the body.  It is estimated that one third of humans are 
infected with TB, however, this infection will remain latent (asymptomatic) for life in 
most people.  The risk of disease activation from latent to active form is considerably 
increased in the presence of immunosuppression such as that caused by HIV infection.(3)   
Once activated, the infection damages tissue, and the body creates granulomatous 
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inflammation in an attempt to contain the spread of the organism.  Without treatment 
among sputum smear positive pulmonary TB cases without HIV, 10 year mortality is 
70%.(4) 
 Diagnostic tools for TB are not ideal.(5)  Culture of sputum in solid or liquid 
medium is the reference standard, but may take as long as six weeks for results.  Sputum 
smear visualizes mycobacteria using acid fast staining, is rapid and cheap and correlates 
with burden of pulmonary disease, but lacks sensitivity.   Chest x-ray is not specific, and 
lacks inter-rater reliability.  However, newer molecular tests such as Xpert MTB/Rif show 
high accuracy and are being rolled out in many high burden countries.(6)  
 The treatment of TB prior to the introduction of streptomycin consisted of 
sanatorium admission for rest, with collapse of affected portions of lung using surgery or 
injection of air into the pleural space.(7) Early chemotherapies included gold salts, 
sulphones, nicotinamide and vitamin D.(8)  The discovery of streptomycin(9) and 
description of its activity in guinea pigs prompted the first clinical trial using 
randomization in the history of medicine, in 1946.(10)  Fifty four patients were 
randomized to bedrest and streptomycin and fifty to bedrest alone.  The streptomycin arm 
had fewer deaths and greater percentage culture negativity, but at five years follow-up, 
the survival benefit was lost due to the emergence of drug resistance.  Modern 
chemotherapy contains multiple drugs at once in order to prevent drug resistance from 
creating recurrence of disease after treatment.     
 It was later discovered that there was no benefit associated with admission to a 
sanatorium through a randomized trial in India which compared one year of two drug 
treatment delivered in the sanatorium versus in the home.(11)  Treatment outcomes were 
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similar and family members living with the patient were not more likely to develop 
TB.(12)  Home treatment uncovered the main treatment challenge in the modern era, 
which is adherence with the entire course of therapy.  After patients feel well, they no 
longer feel motivated to complete additional treatment.  Approaches to manage this 
include directly observed therapy and shortened length of treatment course (“DOTS”), 
currently limited to a minimum of six months.     
 Modern chemotherapy of drug susceptible TB includes four drugs (isoniazid, 
rifampin, pyrazinamide and ethambutol) given for two months followed by two drugs 
(isoniazid and rifampin) given for four months, each dose under direct supervision, with 
reporting of treatment outcomes to international surveillance.(13)   With appropriate 
adherence, cure rate without relapse is greater than 96%.(12) TB determined to be 
resistant to standard treatments requires considerably longer treatment, up to 24 months 
with more expensive and toxic second line drugs, and carries a poorer prognosis.(14)  
 The use of vitamin D for TB treatment began in 1849 with the observation that oil 
from fish liver improved appetite and strength among TB patients.(15)  Vitamin D3 was 
isolated from fish oil and the physiology of vitamin D was elucidated.   Vitamin D3 is 
obtained in the diet or synthesized in the skin by ultraviolet light’s influence on 7-
dehydrocholesterol.  In the liver it is hydroxylated into 25-hydroxyvitamin D [25(OH)D] 
and then in the kidney into 1,25-dihydroxyvitamin D [1,25(OH)2D], the active form 
which binds to the vitamin D receptor on many different tissues.  Binding results in 
transcription of a calcium binding protein which mediates calcium absorption from the 
gut.  The production of 1,25(OH)2D is stimulated by parathyroid hormone (PTH) and 
decreased by calcium.  Adequate 1,25(OH)2D levels will suppress PTH.  Deficiency of 
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vitamin D leads to bone resorption, osteoporosis and fractures, and a disease known as 
rickets (or osteomalacia) in which new bone is not mineralized appropriately.  Deficiency 
may be defined as the level of 25(OH)D at which serum PTH rises, which is about 
75nmol/l, according to most surveys.(16)   
Despite adequate sun exposure, rickets and osteomalacia are prevalent in South 
Asia.  Groups of Indians including physicians, soldiers, pregnant women and newborns 
were assessed in winter and summer, and all groups were found to have deficiency of 
25(OH)D, with consequent low calcium and high PTH levels.(17) Populations in other 
sunny climates such as Hawaii have also been observed to be D deficient.(18)  Persons 
with TB in London, mostly born in India and East Africa, demonstrated low D levels, and 
a vegetarian diet was considered contributory.(19)  
Besides its’ role in calcium regulation, 1,25(OH)2D has an antiproliferative effect 
and downregulates inflammatory markers.   It may be synthesized outside the kidney 
under the influence of cytokines and it is important for the paracrine regulation of cell 
differentiation and function.  It is this immunoregulatory function which may explain the 
potential role of vitamin D in many diseases.(20-22)  
 The mechanism of action of vitamin D in TB has been explored in vitro.(23) 
Vitamin D does not have direct anti-mycobacterial effects in the absence of inflammatory 
cells, unlike vitamin C which has a direct killing effect(24).  Macrophages infected with 
TB within granulomas express 25-hydroxy-vitamin D 1α-hydroxylase, an enzyme which 
converts 25(OH)D into 1,25(OH)2D, and vitamin D receptors.(25, 26)  The rate at which 
this enzyme converts vitamin D is dependent on availability of substrate.(27)  The local 
influence of 1,25(OH)2D  is to enhance mycobacterial killing by monocytes and 
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macrophages, leading to a more successful interaction with the pathogen, and a more 
accelerated resolution of inflammatory responses during treatment.(28) 
 Indirect clinical association between vitamin D and TB began with the 
observation of hypercalcemia among TB patients at diagnosis, or during early 
treatment.(29) Vitamin D deficiency has been associated with an increased risk of 
reactivation of latent TB observed among immigrants to the United Kingdom.(30, 31)  
Several case-control studies confirmed this association.(32, 33) Subsequently, genotypes 
of the vitamin D receptor (VDR) were associated with increased susceptibility to TB in 
certain ethnic groups,(34)and polymorphisms in the vitamin D binding protein were 
similarly associated.(35) It is not clear how these polymorphisms influence interaction 
with vitamin D.  VDR polymorphisms represented in South India are varied, including 
BsmI, ApaI, TaqI and FokI.(36)        
 The most appropriate effectiveness outcome in a clinical trial of novel TB therapy 
is rate of relapse after treatment, however this design is cumbersome as it requires lengthy 
follow-up after treatment and large patient numbers, since relapse is rare.  Surrogate 
clinical markers of this reference outcome have been described including proportion of 
patients with negative sputum culture at two months,(37) time to sputum culture 
conversion from positive to negative using survival analysis, the rate of reduction in 
bacterial counts in sputum during the early phase of treatment,(38) or time to detection of 
growth in serial cultures, representing numbers of bacteria present at the time of 
collection.(39)  Time to culture conversion provides a greater number of data points and 
is less susceptible to sputum collection variation as compared to a single culture at two 
months.   Challenges with the use of time to culture conversion as an outcome include 
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variation in laboratory diagnostic techniques, variation in timing and method of collection 
of specimens, inter-patient differences in response to therapy.  The need for novel 
biomarkers of treatment response in order to detect the efficacy of new TB treatments has 
been well outlined.(40)  Due to the use of multiple drugs at the same time for TB 
treatment, measuring the benefit of a change in a single drug is expensive and complex.   
 Seven randomized clinical trials reporting on the effectiveness or safety of the 
addition of vitamin D supplementation to standard TB treatment have been published, 
however methods, dosage and outcomes have varied considerably, as summarized in 
Table 1.  Only one of the available randomized trials of vitamin D supplementation in TB 
treatment reported using a recognized surrogate marker of outcome, time to culture 
conversion.(41)  Others reported change in serum calcium or vitamin D levels,(42, 43) 
change in weight or symptoms,(44) anti-TB immunity, (45) or clinical scoring 
systems.(46) A trial by Martineau and colleagues recruited 146 smear positive pulmonary 
TB patients in the UK, and provided a placebo-matched 2 weekly dose of 2.5 mg of 
vitamin D, given four times during the first eight week of therapy.  62 patients assigned to 
vitamin D and 64 assigned to placebo were analyzed, with a median time to culture 
conversion of 36.0 days in the vitamin D arm and 43.5 days in the placebo arm (adjusted 
hazard ratio 1.39, 95% C.I = 0.90-2.16, p=0.14 by log rank test).  A significant difference 
was observed among a subgroup with the tt genotype of the Taq1 VDR 
polymorphism.(41)       
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Table 1 : Previous Randomized Trials of Vitamin D Supplementation in 
Tuberculosis 
Study Country Patients 
Analyzed 
Intervention Outcome 
Gwinup(42) USA 23 adults 125 µg D2 
daily 
No change in serum 
calcium 
Narang(43) India 30 adults 10-95 µg D* 
daily 
Serum calcium increased in 
63% 
Morcos(44) Egypt 24 children 25 µg D* 
daily 
No change in weight or 
symptoms 
Nursyam(47) Indonesia 67 adults 250 µg D* 
daily 
Smear conversion increased 
at 6 weeks 
Martineau(48) UK 25 adults 2.5 mg D2
once 
109 nmol/l increase in 
25(OH)D at 8 weeks 
Wejse(46) Guinea-
Bissau 
365 adults 3 doses of 2.5 
mg D3
No effect on TB score 
Martineau(41) UK 146 adults 4 doses of 2.5 
mg of D3
No effect on time to culture 
conversion 
Salahuddin(45) Pakistan 259 adults 2 doses of 15 
mg of D3 
Greater weight gain, 
improved chest x-ray 
Ralph(49) Indonesia 155 adults 2 doses of 
1.25 mg of D3 
No effect on percent 
culture conversion at 4 
weeks.  No effect on 
clinical outcome score 
*Form of D used not reported
A high dose of supplemental vitamin D could be associated with risk of 
hypercalcemia, possibly causing harm to TB patients.  Three randomized trials considered 
change in calcium levels during vitamin D therapy, and only one reported a significant 
increase.(42, 43, 48) This observation has been controversial, since the dose of vitamin D 
used was considerably lower than trials in healthy volunteers in which hypercalcemia was 
not detected.(23) In the Martineau trial, an increase in urinary calcium to creatinine ratio 
was observed after day 28, but serum calcium was not influenced by allocation to the 
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vitamin D arm.(41) A recent case of severe hypercalcemia has been described after one 
11.5 mg oral dose of vitamin D, a dose four times higher than used in any trial.(50)   
The most appropriate dose for vitamin D supplementation is unknown.  A single 
2.5 mg dose of D3 (100,000 iu) induced an mean increase of 109.5 nmol/l in 25OH D 
levels in D deficient TB patients at one week, without hypercalcemia.(48)  
Considering the evidence that vitamin D has an immunomodulatory effect among 
patients with TB and is expensive and easily available, with little evidence of toxicity 
when used at an appropriate dose, further clinical trials of vitamin D therapy seemed 
justified.  With evidence that vitamin D receptor genotypes are ethnically divergent, 
vitamin D supplementation could have different effects in different geographic locations.  
India is a country with a high TB incidence and a well-functioning TB control program.  
Given the established effectiveness of standard TB treatment, vitamin D would be added 
to standard treatment.  If proven to accelerate culture conversion, supplemental vitamin D 
might be able to reduce length of treatment.  
It is unclear if TB patients would benefit most from a D supplement to restore 
normal D levels among those with D deficiency, or if supraphysiologic D levels would be 
more beneficial.  In the previous randomized clinical trial in the UK, 146 patients with 
pulmonary TB in the D arm had a mean D level of 21.1 nmol/l before supplementation, 
which increased to 101.4 nmol/l, which would be above the standard definition of 
sufficiency.(41) This was not associated with a significant reduction in time to culture 
conversion.      
The research question proposed was as follows: Among treatment naïve, HIV 
negative, smear positive pulmonary TB patients in India, does the addition of four oral 
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doses of 2.5 mg of vitamin D3 during the first eight weeks of TB treatment, as compared 
to matching placebo, reduce the time to conversion of sputum culture?  The role of Peter 
Daley in the trial was writing the protocol, acquiring the funding, acquiring ethics 
permissions, supervising data collection, performing analysis and writing the manuscript.    
Methods 
Trial Design 
The study was a randomized, parallel, double-blinded, placebo-controlled 
comparison of adjunctive high dose vitamin D supplementation with standard anti-TB 
treatment (ATT) among new smear positive pulmonary TB patients.  Patients were 
allocated equally into two arms.  The protocol was designed and followed in keeping with 
Good Clinical Practice standards and national ethical guidelines, with expansion from 
four sites into thirteen sites during the trial, due to initially slow recruitment.  This was 
the only change in protocol after the trial began.  Expanded sites were local RNTCP 
clinics, and were visited by study personnel.  Permission was granted by the Drugs 
Controller General of India, the Health Ministry Screening Committee of the government 
of India, and the ethics committees of Christian Medical College Vellore, India and 
Dalhousie University, Canada. 
Trial Registration (see Appendices) 
Clinicaltrials.gov NCT00366470  
Clinical Trials Registry of India CTRI/2007/091/00008 20-10-2009 
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Drugs Controller General of India DCGI-F-NO: 12-01-2006-DC(pt.51) dt 11-09-
2009 
India Health Ministry Screening Committee 5/8/9/66/2007-ECO-1 dt 13-07-2009 
Participants 
Previously treatment naïve, HIV negative, pulmonary TB cases (aged 18-75) with 
at least one recorded sputum smear positive, were eligible for participation if they had 
taken one dose of TB treatment or fewer.  Those with pre-existing liver or kidney disease, 
concurrent steroid or cytotoxic drug treatment, metastatic malignancy, pregnancy or 
lactation, active diarrhea, hypercalcemia (corrected serum calcium >2.62 mmol/l) or not 
expected to survive the duration of the study were excluded.  Patients determined to have 
multi-drug resistant TB on initial culture were removed from the trial and provided 
second line treatment.  Patients were recruited from nine national TB treatment units in 
Vellore (136/100,000/year TB case notification) and Krishnagiri (79/100,000/year TB 
case notification) Districts of Tamil Nadu.(2)  Patients recruited from the Christian 
Medical College hospital were followed up in the DOTS clinic, and patients recruited 
from peripheral clinics were visited in their homes for study visits after recruitment from 
the DOTS clinic.   
Data was collected by two trained study personnel (Jaganathan Vijayakumar at all 
peripheral sites, and Asha Latha at the Christian Medical College site), who were trained 
in study protocol and Good Clinical Practice standards.   Study personnel worked directly 
with RNTCP treatment officers, who were responsible for providing ATT.  RNTCP 
officers did not participate in study data collection or intervention.   
Intervention 
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 Both arms received standard category 1 ATT according to national guidelines(2), 
by direct observation through the RNTCP.  This treatment category includes new sputum 
smear positive pulmonary TB diagnoses.  Category 1 ATT includes: 
• 2 months of Isoniazid 600 mg, Rifampin 450 mg, Pyrazinamide 1500 mg, 
Ethambutol 1200 mg, each given three times per week, followed by 4 months 
of Isoniazid 600 mg, Rifampin 450 mg, each given three times per week 
Patients randomized to vitamin D received four doses of tasteless, odourless 2.5 
mg cholecalciferol (vitamin D3) oil (100,000 iu/dose) (D DropsTM, provided by Reinhold 
Veith, Toronto) orally, once every two weeks for eight weeks, given by direct observation 
by study personnel.  Patients randomized to placebo received identical carrier oil 
(Migliol, provided by Reinhold Veith, Toronto).  The first dose of vitamin D was 
provided with the first dose of ATT, and subsequent doses were given 14, 28 and 42 days.   
Both interventions were stored in identical dark glass dropper bottles at room temperature 
and protected from light.  The vitamin D was stored by the study personnel between 
doses.  One vial was tested for vitamin D content at the end of the trial and was found to 
contain more than 95% of the original concentration of active ingredient (Elaine Veith, 
personal communication).  
There was no advice provided to patients to change their usual diet or sun 
exposure during the trial.  
Randomization 
 200 bottles containing vitamin D and 200 containing placebo were randomized by 
computer (Random Allocation Software by M. Saghaei) in Canada into permuted blocks 
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of four without stratification, then labelled with serial study numbers in their randomized 
order, before being shipped to India.  As each patient was recruited to the trial, the next 
serially numbered bottle in sequence was assigned by the study personnel.           
Blinding 
 Neither the patient nor the study personnel including all investigators in India, 
were aware of treatment assignment.  The randomization code was maintained in Canada 
by one investigator (RV).  Patients, clinical and laboratory study personnel in India were 
not aware of assignment.  After the study was completed and database locked for 
analysis, the code was broken and analysis was performed with knowledge of assignment.   
Outcome 
 The primary efficacy outcome was time to liquid culture conversion, measured 
from the first dose of ATT to the collection of the first negative culture.   Sputa were 
collected by spontaneous expectoration following instructions from study personnel, at 
treatment days 0, 14, 28, 42, 56 and 180, with an additional sputum collected at day 90 if 
the day 56 sputum was culture positive.  Secondary outcomes included time to culture 
conversion measured from the first dose of ATT to the collection of the first of two 
consecutive negative cultures, time to smear conversion, proportion of patients culture 
positive at 56 days, Karnofsky performance status and body mass index (BMI) at 56 days, 
rate of rise in time to detection in culture(39), and 25(OH)D concentration at day 180.   
The primary safety outcome was incidence of hypercalcemia (corrected serum 
calcium > 2.62 mmol/l).  Secondary safety outcomes included rates of serious adverse 
events (SAE), defined as death, admission to hospital, life-threatening illness, persistent 
disability, congenital anomaly, with predefined disease related complications of TB 
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infection,  and adverse events (AE), defined as any untoward medical occurrence after 
study medication.   SAE were reported within 24 hours to the ethics committees of the 
Christian Medical College and Dalhousie University.      
Procedure 
  At the screening visit, after obtaining informed written consent in a language the 
patient understood, demographic data, Karnofsky performance index(51), medical 
history, concurrent medications and height and weight were recorded.   One sputum 
sample for acid fast smear and liquid mycobacterial culture and susceptibility to isoniazid 
and rifampin, HIV serology, 25 OH-D, calcium, albumin, creatinine, ALT, and for all 
women of reproductive age, a urine pregnancy test were performed.  HIV pre and post-
test counselling was provided to all patients.  Sputum was tested for acid fast smear 
(visible organisms) and liquid culture (incubated for growth of organisms).  Calcium was 
repeated at day 4 and 28, and 25 OH-D at day 180.    
Laboratory Methods 
 Sputum smears were performed using auramine phenol stain and fluorescent 
microscopy and interpreted according to WHO guidelines.  Sputum was pretreated with 
4% NaOH/N-acetyl-L-cysteine for 15 minutes.  Sputum culture was performed using MB 
BACTEC 9000 automated system (Becton-Dickenson) according to local laboratory 
procedure, with incubation for 42 days.   Contaminated cultures were re-treated and 
reinoculated into liquid culture.  Drug susceptibility testing for rifampin and isoniazid 
followed the 1% proportion method.  Resistant isolates were confirmed using Gene 
XpertTM (Cepheid, USA).  All testing was performed at a single laboratory by a single 
technologist, trained in mycobacteriology.  The mycobacteriology laboratory at the 
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Christian Medical College Vellore is certified by the Stop TB Partnership Global 
Laboratory Initiative.     
Sample Size 
The effect size estimate was a reduction in median time to culture conversion 
from 42 days to 28 days due to the effect of adjunctive vitamin D.  This estimate was 
based on collection of sputum at days 42 and 28, and was identical to the estimate of 
effect in another trial.(41)  With a power of 0.80, a two sided analysis and a significance 
value of 0.05, 96 patients in each arm were required.  Loss to follow-up and contaminated 
cultures were estimated to cause a loss of thirty percent of results, therefore 250 patients 
were recruited in total (96+96+30%).  This calculation was based on a log-rank analysis, 
assumed an accrual time of 365 days, a follow up time of 180 days, and an equal 
assignment of patients to two groups.  PS software was used (Vanderbilt University). The 
planned interim analysis at 50% recruitment was not performed because recruitment was 
completed before culture data from the first half of recruitment was available.   
Statistical Methods 
A log-rank test was used (SPSS 19.0.0, IBM) to compare time to culture 
conversion in the vitamin D and placebo arms.  Efficacy was analysed as modified 
intention to treat (all patients who received one dose of intervention and had at least two 
sputum culture results available).  Safety was analysed for all patients who received one 
dose of intervention.  
Role of the Funding Source 
Dalhousie University had no influence in the design, conduct or interpretation of 
the study.  The corresponding author had full access to all the data.      
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Funding and Conflict of Interest 
The study was funded by Dalhousie University, Canada, as a University Internal 
Medicine Foundation Junior Member Grant.  The intervention was donated by Reinhold 
Veith.  The funding agencies had no role in the design, interpretation or reporting of the 
study.       
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Results 
Participant Flow 
Patients were recruited as outlined in Figure 1.  259 patients were assessed for 
eligibility, and 249 patients randomized, 121 to vitamin D and 126 to placebo.  One grew 
a nontuberculous mycobacterium (M. fortuitum), and one grew confirmed multidrug 
resistant TB.  Recruitment occurred between 20 January 2010 and 23 August 2011.  The 
last patient follow-up visit was completed on 20 February 2012.  The recruitment was 
stopped when the sample size was reached.   
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Figure 1: Participant Flow 
Assessed for eligibility, n = 259
Randomized, n = 247
Allocated to Vitamin D (n = 121) 
Excluded:
Withdrawn (n = 9)
Kidney failure (n = 1)
MDRTB (n = 1)
Non-TB Mycobacterium (n=1)
Analyzed primary outcome (n = 101) Analyzed primary outcome (n = 110)
Allocated to Placebo (n = 126) 
R
ec
ru
itm
en
t
R
an
do
m
 a
ss
ig
nm
en
t
In
te
rv
en
tio
n
Fo
llo
w
-u
p
Excluded from analysis (n=20)
Only one culture available (n=8)
Culture negative throughout (n= 12)
Excluded from analysis (n=16)
Only one culture available (n=5)
Culture negative throughout (n=11)
Baseline Data 
The study population is described in Table 2.   All patients were ethnically Tamil 
or Telugu.  There were slightly more males in the placebo group (80.2% vs. 72.7% in the 
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D group).   Mean age was similar (43.7 years in placebo, 41.6 years in D) and baseline 
body mass index was similar and low (17.8 in placebo, 18.0 in D).  The vast majority of 
patients earned less than $95 US per month (94.4% in placebo and 90.9% in D).  There 
were slightly more smokers in the placebo group (31.0% vs. 22.3% in the D group).  
There was slightly more isoniazid monoresistance among the D group (6.3% in placebo, 
11.6% in D).  Baseline albumin corrected calcium and vitamin D levels were similar.  
Mean vitamin D in all patients was well below the threshold of sufficiency.  Differences 
between groups were considered clinically insignificant.     
Table 2: Socio demographic characteristics 
Variable Name Vitamin D (N=121) 
n (%) 
Placebo (N=126) 
n (%) 
Male 88 (72.7) 101 (80.2) 
Mean Age in Years (SD) 41.6 (15.1) 43.7 (14.3) 
Mean Baseline Body Mass Index 
(SD) 
18.0 (2.9) 17.8 (3.0) 
Occupation 
Professional 5 (4.1) 3 (2.4) 
Skilled worker 23 (19.0) 30 (23.8) 
Clerical / Shop Owner / Farm Owner 6 (5.0) 6 (4.8) 
Unskilled worker / Manual labor 41 (33.9) 43 (34.1) 
Retired / Pensioner 2 (1.7) 2 (1.6) 
Unemployed 42 (34.7) 39 (31.0) 
Others 2 (1.7) 3 (2.4) 
Monthly Income 
< Rs. 5000 (<$95 US) 110 (90.9) 119 (94.4) 
Rs. 5000 – 10000 ($95 - $185 US) 7 (5.8) 5 (4.0) 
Rs. 10001 – 20000 ($185 - $370 US) 4 (3.3) 2 (1.6) 
Education Completed 
Illiterate 24 (19.8) 32 (25.4) 
Primary school 39 (32.2) 37 (29.4) 
Class VI-IX 25 (20.7) 25 (19.8) 
Class X 20 (16.5) 19 (15.1) 
Diploma / Bachelor’s degree 12 (9.9) 8 (6.3) 
Master’s degree 1 (0.8) 3 (2.4) 
28 
Professional or Doctoral degree - 2 (1.6) 
Baseline Karnofsky Score 
50 4(3.3) 1(0.8) 
60 20(16.5) 16(12.7) 
70 61(50.4) 65(51.6) 
80 33(27.3) 40(31.7) 
90 3(2.5) 4(3.2) 
Smoking Cigarettes (Presently) 
Yes 27(22.3) 39(31.0) 
Chewing Betel Nuts (Presently) 
Yes 2(1.7) 4(3.2) 
Consuming Alcohol (Presently) 
Yes 25(20.7) 30(23.8) 
Variable Name Vitamin D (N=121) 
n (%) 
Placebo (N=126) 
n (%) 
Resistant to Isoniazid 14 (11.6) 8 (6.3) 
Isoniazid Susceptibility Not Available 20 (16.5) 20 (15.9) 
Resistant to Rifampin 1 (0.8) 1 (0.8) 
Rifampin Susceptibility Not Available 5 (41.7) 20 (15.9) 
Corrected Calcium Baseline (mmol/l) 
Mean (SD) 
2.27 (0.15) 2.28 (0.17) 
25 OH D Level Baseline (nmol/l) 
Mean (SD) 
25.3 (18.7) 24.9 (20.5) 
Visit 1 Final Culture Results 
Positive 101 (83.5) 108 (85.7) 
Negative 19 (15.7) 18 (14.3) 
Missing 1 (0.8) - 
Visit 6 Final Culture Result 
Positive 63 (52.1) 76 (60.3) 
Negative 42 (34.7) 37 (29.4) 
Missing 16 (13.2) 13 (10.3) 
Visit 7 Final Culture Result 
Positive 41 (33.9) 46 (36.5) 
Negative 61 (50.4) 59 (46.8) 
Missing 19 (15.7) 21 (16.7) 
Visit 8 Final Culture Result 
Positive 24 (19.8) 26 (20.6) 
Negative 73 (60.3) 68 (54.0) 
Missing 24 (19.8) 32 (25.4) 
Visit 9 Final Culture Result 
29 
Positive 15 (12.4) 16 (12.7) 
Negative 76 (62.8) 80 (63.5) 
Missing 30 (24.8) 30 (23.8) 
Visit 10 Final Culture Results 
Positive 12 (9.9) 17 (13.5) 
Negative 87 (71.9) 82 (65.1) 
Missing 22 (18.2) 27 (21.4) 
Visit 1 Smear 
Positive 101 (83.5) 108 (85.7) 
Negative 19 (15.7) 18 (14.3) 
Missing 1 (0.8) - 
Visit 6 Smear 
Positive 63 (52.1) 77 (61.1) 
Negative 42 (34.7) 36 (28.6) 
Missing 16 (13.2) 13 (10.3) 
Visit 7 Smear 
Positive 41 (33.9) 48 (38.1) 
Negative 61 (50.4) 58 (46.0) 
Missing 19 (15.7) 20 (15.9) 
Visit 8 Smear 
Positive 24 (19.8) 27 (21.4) 
Negative 73 (60.3) 67 (53.2) 
Missing 24 (19.8) 32 (25.4) 
Visit 9 Smear 
Positive 14 (11.6) 17 (13.5) 
Negative 78 (64.5) 81 (64.3) 
Missing 29 (24.0) 28 (22.2) 
Visit 10 Smear 
Positive 12 (9.9) 16 (12.7) 
Negative 88 (72.7) 83 (65.9) 
Missing 21 (17.4) 27 (21.4) 
Numbers Analysed 
All patients with two culture results available were analyzed for the primary 
outcome, time to culture conversion (time to first negative culture), including those who 
were culture negative on the first visit but culture positive on the second visit.   Eight 
patients in the D group and 5 in the placebo group did not have culture results available 
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following the initial visit and were excluded.  Twelve patients in the D group and 11 in 
the placebo group were never culture positive and were excluded.  The primary outcome 
analysis was performed on 101 patients in the D group and 110 patients in the placebo 
group.  
Because there were positive cultures which occurred following negative cultures, 
an alternative survival analysis was also considered as a secondary outcome (time to 
culture conversion (time to first of two consecutive negative cultures)).  The secondary 
outcome analysis of time to culture conversion (time to first of two negative cultures) was 
performed on 81 patients in the D group and 82 patients in the placebo group.  
All patients with two smear results available, at least one of which was positive, 
were analyzed for time to smear conversion (time to first negative smear).  Eight patients 
in the D group and 5 in the placebo group did not have smear results available following 
the initial visit, and were excluded.  Twelve patients in the D group and 11 in the placebo 
group did not have a positive smear at any point during the trial (except the smear to 
assess inclusion into the trial), and were excluded.  The secondary outcome analysis of 
time to smear conversion (time to first negative smear) was performed on 101 patients in 
the D group and 110 patients in the placebo group.       
Because there were positive smears which occurred following negative smears, an 
alternative survival analysis was also considered (time to smear conversion (time to first 
of two consecutive negative smears)).  The secondary outcome analysis of time to smear 
conversion (time to first of two consecutive negative smears) was performed on 85 
patients in the D group and 87 patients in the placebo group.
Primary Outcome 
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The primary outcome was time to culture conversion (first negative culture), and 
is presented in Table 3 and Figure 2.  The median time to culture conversion in the 
vitamin D group was 43.0 days (95% C.I. = 33.2 to 52.8).  The median time to culture 
conversion in the placebo group was 42.0 days (95% C.I. = 33.9 to 50.1) (p=0.95 by log 
rank test).  This demonstrated no statistically significant difference between the time to 
culture conversion between the D group and the placebo group.     
Table 3: Primary Outcome – Time to Culture Conversion (First Negative Culture) 
Group 
Number 
of 
subjects 
Events (%) Censored (%) 
Median Time to 
Culture 
Conversion in 
days (95% CI) 
Log Rank 
Test 
Vitamin D 101 85 (84.2) 16 (15.8) 43.0 (33.3 to 
52.8) 
p = 0.952 
Placebo 110 87 (79.1) 23 (20.9) 42.0 (33.9 to 
50.1) 
 
  
 
32 
 
Figure 2 : Primary Outcome – Time to Culture Conversion (First Negative Culture) 
 
Secondary Outcomes 
The secondary outcome of time to culture conversion (first of two negative 
cultures) is presented in Table 4 and Figure 3.  The median time to culture conversion 
(first of two negative cultures) in the vitamin D group was 33.0 days (95% C.I. = 21.5 to 
44.5).  The median time to culture conversion in the placebo group was 40.0 days (95% 
C.I. = 29.5 to 50.5) (p=0.33 by log rank test).   
Table 4: Secondary Outcome – Time to Culture Conversion (First of Two 
Consecutive Negative Cultures) 
Group Number Events (%) Censored Median Time to Log Rank 
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of 
subjects 
(%) Culture 
Conversion in 
days (95% CI) 
Test 
Vitamin D 81 69 (85.2) 12 (14.8) 33.0 (21.5 to 
44.5) 
p = 0.331 
Placebo 82 66 (80.5) 16 (19.5) 40.0 (29.5 to 
50.5) 
 
Figure 3: Primary Outcome – Time to Culture Conversion (First of Two 
Consecutive Negative Cultures) 
 
The secondary outcome of time to smear conversion (first negative smear) is 
presented in Table 5 and Figure 4.  The median time to smear conversion in the vitamin D 
group was 43.0 days (95% C.I. = 33.3 to 52.7).  The median time to smear conversion in 
the placebo group was 43.0 days (95% C.I. = 36.1 to 49.9) (p=0.95 by log rank test).   
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Table 5: Secondary Outcome – Time to Smear Conversion (First Negative 
Smear) 
Group 
Number 
of 
subjects 
Events (%) Censored (%) 
Median Time to 
Smear 
Conversion in 
days (95% CI) 
Log Rank 
Test 
Vitamin D 101 85 (84.2) 16 (15.8) 43.0 (33.3 to 
52.7) 
p = 0.949 
Placebo 110 88 (80.0) 22 (20.0) 43.0 (36.1 to 
49.9) 
 
Figure 4: Secondary Outcome – Time to Smear Conversion (First Negative Smear) 
 
 The secondary outcome of time to smear conversion (first of two consecutive 
negative smears) is presented in Table 6 and Figure 5.   The median time to smear 
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conversion in the vitamin D group was 41.0 days (95% C.I. = 21.5 to 44.5).  The median 
time to smear conversion in the placebo group was 45.0 days (95% C.I. = 29.4 to 52.6) 
(p=0.45 by log rank test).   
Table 6: Secondary Outcome – Time to Smear Conversion (First of Two 
Consecutive Negative Smears) 
Group 
Number 
of 
subjects 
Events (%) Censored (%) 
Median Time to 
Culture 
Conversion in 
days (95% CI) 
Log Rank 
Test 
Vitamin D 85 69 (81.2) 16 (18.8) 41.0 (21.5 to 
44.5) 
p = 0.445 
Placebo 87 66 (75.9) 21 (24.1) 45.0 (29.4 to 
52.6) 
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Figure 5: Secondary Outcome – Time to Smear Conversion (First of Two 
Consecutive Negative Smears)
 
Because there were no clinically significant differences between groups at 
baseline, adjustment for baseline differences was not performed.  Survival curves crossed 
each other in all four analyses, violating the assumptions of the Cox regression model.     
The percent sputum culture negativity at Day 56 in Vitamin D group was 80.8% 
and in the placebo group it was 82.9% [difference -2.1 (95% C. I = -14.2 to 10.0)].  See 
Table 7. There is no statistically or clinically significant difference between percent 
culture negativity at day 56.   
Table 7: Secondary Outcome - Percent Sputum Culture Negative at day 56 
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 Vitamin D n/N 
Vitamin D 
% 
Placebo 
n/N Placebo % 
Difference 
(Vitamin D - Placebo) 
95% CI 
Sputum culture 
Negative at 56 days 
59 / 73 80.82 68 / 82 82.93 -2.11 
(-14.18 to 9.96) 
 
The secondary outcome of time to detection of growth is presented in Figure 6.  
Time to detection of growth was quite variable, providing a poor fit to a regression line.  
The rate of rise in time to detection in the vitamin D group was 0.17.  The rate of rise in 
time to detection in the placebo group was 0.11 (difference 0.066, p = 0.59).    
Figure 6 – Secondary Outcome - Time to Detection in Liquid Culture by 
Intervention 
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Baseline vitamin D level was available for 124 of the patients randomized to 
placebo (98.4%) and day 180 vitamin D level was also available for 79 (55.5%), 
providing comparison data for 77 patients.  The level increased 2.67 nmol/l (SD 16.09).  
Baseline vitamin D level was available for 119 of the patients randomized to D (98.3%) 
and day 180 vitamin D level was also available for 67 (55.3%), providing comparison 
data for 65 patients.  The level increased 5.68 nmol/l (SD 13.63).  The difference in 
increases between the groups was 3.02 nmol/l (p = 0.235), see Table 8.  There was not a 
significant difference between the increases in vitamin D in the D group as compared to 
the placebo group.  Because the upper limit of the assay (100 nmol/l) was reached in 8 
patients, these results may be a slight underestimate of the true mean.  Because 
measurements were not taken serially throughout the study, the vitamin D level may have 
increased and then decreased by day 180.    
Table 8: Secondary Outcome – Change in Vitamin D Levels 
 
Intervention n Mean Difference between 
Baseline D level and Day 180 D 
level (nmol/l) 
SD Difference T test 
Placebo 77 2.67 
 
16.09 3.02 p = 0.235 
Vitamin D 65 5.68 13.63   
 
Baseline BMI (weight in kg/height in meters2) was available for all patients, with 
a mean of 17.9 (SD 2.9).  Body mass index was available at day 58 for 213/249 patients 
(85.5%), with a mean of 18.7 (SD 3.1) (p <0.001 by t test), indicating a significant weight 
gain over the course of the study.  The difference in increases in BMI between the groups 
was 0.087 more in the placebo group (p=0.597).  
 
39 
 
Baseline Karnofsky performance index (100 point scale of functional capability 
from perfect health at 100 to death at 0) was available for all patients, with a mean of 71.7 
(SD 7.8).  Karnofsky performance index was available at day 58 for 212/249 patients 
(85.1%), with a mean of 83.4 (SD 8.1) (p <0.001 by t test), indicating a significant 
performance improvement over the course of the study.  The difference in increases in 
Karnofsky performance index was 1.90 more in the vitamin D group (p=0.115).        
Safety 
There were no cases of hypercalcemia detected in either arm through calcium 
monitoring or symptoms.  Figure 7 demonstrates the trend in mean calcium levels through 
the study.  There was no statistically or clinically significant change in calcium levels in 
either group.     
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Figure 7: Safety - Calcium levels  
 
Table 9 summarizes serious adverse events.  Four patients died during the study, 
three on the D arm and one on the placebo arm.  No death was considered directly 
attributable to study intervention.  The first death on the D arm was attributed to alcohol 
ingestion.  The second death on the D arm occurred at 3 months and 6 days following the 
final dose of D, of unknown causes.  The third death on the vitamin D arm occurred at 17 
days following the final dose of D, of unknown causes.  None of the patients who died 
had hypercalcemia when measured at day 28. 
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Table 10 summarizes adverse events.  There were four adverse events on the D 
arm and three adverse events on the placebo arm.  No adverse event required a change in 
medical therapy which deviated from the study protocol.   
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Table 9: Serious Adverse Events (Chronological Order) 
Date 
of 
Onse
t 
Study 
Numb
er 
Nature of 
SAE 
Date 
Reported 
to Ethics 
Committ
ee of 
Christian 
Medical 
College 
Vellore 
Interventi
on  
Serious 
Adverse 
Event 
Determine
d 
Interventi
on 
Related? 
Description 
28-
03- 
2010 
5 Hospitalizati
on due to 
Seizure 
03-04- 
2010 
Placebo No Enrolled on 24-
02-2010, first 
dose placebo 25-
02-2010 and the 
second on 16-03-
2010.  Visited at 
home on 29-03-
2010 and found to 
be drowsy.  
Admitted 30-03-
2010 to 02-04-
2010.  All 
metabolic 
parameters and 
CT scan of head 
normal.  
Corrected serum 
Ca 2.05 mmol/l.  
15-
05- 
2010 
5 Death 07-07-
2010 
Placebo No Final study dose 
given on 08-04-
10. Follow-up 
visit 16-04-10 in 
good medical 
condition.  
Informed he had 
died during his 
sleep 19-06-10.                                             
23-
09- 
2010 
31 Death 23-12- 
2010 
Vitamin D No First dose of study 
drug on 14-07-10. 
Withdrew consent 
and did not 
receive further 
study drug.  
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Followed as per 
protocol for two 
months. Informed 
on 21-12-10 that 
he had died on 23-
09-10. Massive 
alcohol 
consumption just 
before death.    
03-
03-
2011 
142 Death 01-06-
2011 
Vitamin D No Tenth visit on 30-
05-11, informed 
that the patient 
died on 03-03-
2011, 4 months 
and 18 days after 
starting ATT.  
10-
03-
2011 
171 Hospitalizati
on due to 
hydro-
pneumothora
x 
14-03-
2011 
Placebo No First dose of study 
drug administered 
on 10-03-2011.  
On the same day 
he complained of 
acute 
breathlessness. 
Admitted with 
massive right 
sided 
hydropneumothor
ax, drained with 
intercostal tube 
and discharged 
home 22-03-11.                                                                                 
May 
21, 
2011 
128 Death May 27, 
2011 
Vitamin D No Ninth follow up 
visit on 19-05-
2011 informed 
that patient died 
on 21-05-11.  
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Table 10: Adverse Events 
Study 
Number 
Intervention Adverse 
Event 1 
Treatment in 
Addition to 
Study 
Protocol 
Adverse 
Event 2 
Treatment in 
Addition to 
Study 
Protocol 
60 Vitamin D Giddiness, 
Vomiting, 
Chest pain, 
Tiredness 
None Tooth 
ache, 
tired, 
giddiness 
None 
74 Vitamin D Back Pain None     
80 Vitamin D Lymph node 
on neck 
None     
79 Placebo Tiredness None     
171 Placebo Acute 
Breathlessness 
Right side 
intercostal 
chest 
drainage 
    
 
Discussion 
Our results suggest that 2.5 mg of vitamin D3 given four times during the 
intensive phase of active TB treatment in a TB endemic country does not reduce the time 
to culture conversion significantly.  One previous randomized trial with similar methods 
agreed with this conclusion.(41) We did not have the capacity to perform vitamin D 
receptor polymorphism testing as in that trial, although with the common ethnicity of our 
patients, we may not have detected much variety.   
We were able to demonstrate that patients with active TB in South India have 
significant D deficiency, with a mean serum level of 25 nmol/l.  We were not able to 
demonstrate a significant increase in serum D levels during the study in either group, 
possibly due to the timing of sampling at day 0 and day 180 only. Subjects were given 
vitamin D by direct observation and no doses were missed.  The sample size was 
calculated based on the estimated effect size reported by a previous trial, which was felt 
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to represent a clinically significant improvement due to the addition of an effective drug 
to standard TB treatment.  The confidence intervals surrounding our estimates of time to 
culture conversion included 10 days below and above the estimate, which could include a 
clinically relevant difference.  It is possible therefore that the trial was underpowered to 
detect a clinically relevant difference.         
Change in time to culture conversion is an outcome which reflects success of late 
sterilization, or the elimination of metabolically inactive bacteria to prevent relapse after 
therapy.  The implication of improved late sterilization is reduced total treatment time 
without loss of 95% treatment efficacy.(52) Reduction in treatment duration could 
improve treatment compliance.  It is not clear what amount of reduction in time to 
conversion would be considered adequate to propose a reduction in treatment duration.    
The primary limitation of our study was missing data.  We estimated 30% loss of 
data due to patient dropout and culture contamination, and we did not exceed this 
estimate (24%).  Patients with active TB are among low socioeconomic strata, and are 
often migratory or suffering additional social and mental health comorbidity.  There was 
no loss of data due to culture contamination, but an unexpected number of patients were 
culture negative (smear positive) at baseline.  This may have reflected inadequate sputum 
collection.  Sputum transportation was within one day of collection, so loss of viability 
due to transportation was not likely.  
The study performed a single culture at each time point instead of two cultures as 
in other TB treatment trials, due to financial limitations.  This may have contributed to 
reduced sensitivity, baseline smear positive culture negatives, and the problem we 
observed of positive cultures occurring following negative cultures during treatment.  We 
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feel the alternative method of survival analysis does compensate somewhat for this 
problem, and the conclusion of no change in time to culture conversion remained the 
same under this alternate method.  Risk factor (regression) analysis was not performed, as 
groups were considered comparable at baseline.   
 The survival analysis technique used can compensate for censored data and 
variable dates of collection, but the conversion in outcome from culture positive to 
negative and back to positive, or from negative to positive to negative, is problematic.  In 
order to correct this weakness in the data we performed two survival analyses, based on 
two interpretations of the endpoint.  The first interpretation, time to first negative culture, 
could reflect the response in the early phase of therapy (rapid killing of metabolically 
active organisms) but may be susceptible to sampling bias based on a single poor 
collection.  The second interpretation, time to first of two consecutive negative cultures, 
could reflect the killing of active and some quiescent organisms and may be a more 
definitive outcome, related to risk of relapse after therapy.  In our results, the second 
interpretation demonstrated a small trend toward more rapid conversion in the vitamin D 
arm, at 33.0 days (95% C.I. = 21.5 to 44.5) as compared to 40.0 days (29.5 to 50.5).  
No previous study has interpreted time to culture conversion using these two 
definitions.  Previous studies have defined the time endpoint as time to all cultures 
negative,(53) or the midpoint between the last positive and the first negative culture.(41) 
The definition of this endpoint determines the comparability of effect sizes between 
studies. 
 Using our definition of the endpoint, the observed time to culture conversion in 
the placebo group occurred precisely when predicted, at 42 days.  We would expect smear 
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conversion to occur much earlier than culture conversion, since smear detects 10,000 
organisms per ml of sputum while culture can detect fewer than 100 organisms per ml of 
sputum.  However, we observed that smear conversion did not occur earlier than culture 
conversion.  This may have been influenced by the timing of sampling of sputum, with no 
assessment between days 28 and 42.     
The addition of high dose vitamin D to standard TB treatment does not appear 
toxic.  No hypercalcemia was observed, and serious adverse events observed were 
determined unrelated to the intervention.  There was significant under-reporting of 
adverse events as compared to trials in North America, which may reflect cultural 
differences in reporting, or missing data.  
The results of our trial would generalize to ethnically uniform, D deficient patients 
with active TB and a low HIV coinfection prevalence.  Traditional sanitorium treatment 
of active TB included sunlight exposure and vitamin D supplementation, and in vitro 
studies have demonstrated benefit, but in two randomized clinical trials using appropriate 
surrogate outcomes, vitamin D supplementation does not add benefit.   
The success of recruitment in our trial was high, with very few patients refusing to 
be randomized.  This reflects a culture in which patients generally accept without 
question the suggestions of their health care provider.  Considerable effort was taken to 
ensure adequate informed consent, although some patients were illiterate.  It is 
challenging to ethically recruit patients in a TB endemic country, where patients may not 
fully understand the scientific rationale behind the treatment or the research intervention.    
Future studies in vitamin D in TB could be performed, and could be designed to 
avoid weaknesses in design and interpretation by collecting multiple cultures at each time 
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point, and following D levels serially.  Future studies should explore higher vitamin D 
dosing.  Ideal clinical trial outcomes and trial outcome definitions in TB are unclear, and 
the definition of immunological and genetic biomarkers may provide additional means of 
comparison of time to clearance of bacteria.        
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Appendix 1 
Consent Form 
Patient Information Sheet and Consent Form 
This document provides information for new tuberculosis patients, to seek their 
participation in a clinical research trial.   If you sign it, you be able to participate in this 
trial. 
1. You are being invited to take part in a research trial
This trial involves research of the drug Vitamin D in TB patients.  Before giving 
consent for participation please read carefully, understand and clarify with us if you have 
any doubt in this trial research.  Take this format home, discuss with your family 
members, relatives, friends &doctors about the trial.    
2. Purpose of this trial?
This study is to determine if vitamin D will help in addition to the normal TB 
treatment to cure TB faster.  Cure is determined by a sputum test. 
3. Why have I been chosen?
 You are being asked to take part in this study because you have pulmonary 
tuberculosis. 
4. Your Participation:
You can choose to be in this trial or not to be in it.  If you do decide to take part, 
you will be asked to sign a consent form. You are free to stop at any time during the trial.  
If you stop, you will still get your TB treatment and care. 
5. Trial Treatment & Randomization:
 Trial treatment involves giving each dose of 3.3 ml Migliol oil orally or with food 
once every 2 weeks for 2 months (4 doses totally) along with normal TB medicine. This 
oil may contain the trial drug Vitamin D or plain oil.  This is decided by random. 
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6. Trial Procedure: 
 
The trial procedure involves 9 visits.  The study visits are also coming on the same 
days as your TB clinic visit.  At each visit you will be asked to provide sputum samples 
to observe the TB status and blood samples to check the calcium levels. 
 
7. Your Responsibilities: 
 
     a. To return for the scheduled study visits and to follow procedures as instructed. 
     b. To take the study medication as prescribed. 
     c. To report all changes in your physical or mental condition, any symptoms, any 
         side effect or injury during the study.  
     d. To continue your regular medication.  
     e. To tell the study coordinator all medicines you take. 
          
8 .Your Rights: 
 
     a. You have the right to refuse or withdraw in this study at any time 
     b. You have the right to get regular medical treatment & care. 
     c. You have the right to understand the way the study works. 
     d. You have the right to ask questions about the study 
 
9. Who can participate? 
 
       New TB patient with positive sputum test within the age of 18 to 75 years 
       HIV patient with TB can also participate if CD4 count is >50 cells. 
       We will screen for some other tests in blood and decide whether you are 
included in the study.  
         
11. Risks: 
 
Vitamin D may cause your calcium level to rise temporarily. If your calcium level 
rises too high we will stop the vitamin D temporarily. We will provide medical care if 
you get sick because of high calcium. 
 
12. Expected Benefits: 
 
Vitamin D is expected to reduce the period of TB Treatment. But we don’t know 
fully. We will only know after this trial completes. 
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13. Information on Substudy for participation (optional): 
 
The optional part of the trial (substudy) is the Vitamin D Receptor Polymorphism 
Substudy. You can choose to participate in the main part of the trial without participating 
in the substudy.  In this substudy we will take an additional of 30 ml of blood sample 
during the first visit.  All blood samples will then be sent to a lab, with a study code 
without identifying your name. 
 
In this study we analyze the blood of people with tuberculosis to see whether there 
are certain markers in part of their blood (called DNA), that can predict whether people 
will develop tuberculosis or not.  These are sometimes called “genetic markers” or Bio 
markers.   
 
14. Will the study pay me? 
 
 The study will provide the necessary transportation costs for every visit (Rs 50). 
15. Confidentiality: 
We will not share your medical information with anyone else. 
16. What will happen to the results of the research trial? 
The results of this research may be published at the end of the study. Your name 
will not be mentioned in any report/publication.  Your information belongs to the trial, 
even if you leave the trial. 
17. Who has reviewed the trial? 
The Ethics Committee of the CMCH has reviewed this proposal because it is 
research using human subjects.  They have approved the proposal. 
 18. What use will be made of the data collected from this trial? 
The trial may help other TB patients in India.   
19. Contact for further information 
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 If you have any questions or concerns now or at any time about the trial, your 
safety or your rights, please ask your study coordinator or the contact person(s) indicated 
below.  
 
 
Principal Investigator: 
DR. DILIP MATHAI 
Infectious Diseases Training and Research Center 
5th floor, above State Bank of India 
CMCH 
Vellore 
Phone: 04162282804 
 
Clinical Trial Coordinator, 
Mr. VIJAYAKUMAR. 
Infectious Disease Training and Research Centre, 
CMCH, 
Vellore. 
Mobile: 09366111098. 
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Subject  
Initials:  
Subject Name:  Date of Birth:  
 
Clinical Trial Coordinator: 
 
Trial Number: 
 
 
                  Title of Research Project: VITAMIN D TRIAL  
 
                                           
                                              CONSENT FORM 
 
         AGREEMENT TO PARTICIPATE IN A CLINICAL TRIAL 
 
1. I confirm I have read and understand the information sheet dated 28th August 
2007 for the above Trial and have had the chance to ask questions.  The study was 
explained to me in a language I can understand. 
2. I understand that I chose to enter the trial and that I am free to leave at any      
time, without my medical care or legal rights being affected. 
3. I agree to allow the study doctors or the CMCH Ethics Committee to look at 
my health records for the trial or for future studies even if I leave the study 
4. I agree to an HIV test. 
5. I understand that some participants will get vitamin D and some won’t. 
6. I will not prevent the use of the information in the trial. 
7. I agree to take part in the above trial. 
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8.         I agree to take part in the Vitamin D Receptor Polymorphism Substudy  
            (involves a blood draw). 
 
  
 I do not agree to take part in the Vitamin D Receptor Polymorphism 
Substudy. 
 
  
 Having agreed to take part in the Vitamin D Receptor Polymorphism 
Substudy, I agree to have my blood sample kept for 10 years for future research as 
outlined above.  
 
 
Subject Name 
 
 
  Signature/thumb 
print 
 
Signed by Subject:  Date: 
Witness name  
 
 
 
Signed by witness  Date: 
Investigator Name 
 
 
 
  
Signed by 
Investigator 
 
 
 
 Date: 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
Visit 1         Day 0    Appendix 5 
Case Report Form Clinical 
 
PART I: IDENTIFICATION FORM 
Name 
                                   
 
  
 Hospital No:                                                                                    
 
Contact Information: 
 
Father’s name: 
Temporary address: 
                     
 
 
 
 
Pin Code: 
 
Permanent address: 
 
                     
 
 
 
 
Pin Code: 
 
 
  
Telephone Number                                                         Mobile Number 
            
 
                    
                      
          
      
                      
          
      
            
Signature of clinical research officer --------------------------- 
Author: Dr. Peter Daley                                                                             Page 1 of 54 
                                                                                                                     
 
Vitamin D Randomized Controlled Trial Case Report Form Version 2 1st Nov 2009 
                                  Mathai D, Daley P, John KR,  Jayaseelan L, Christopher DJ, Micheal JS, Joel N,  Arun JoseN 
 
 
STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
Email ID 
                                   
 Mobile No of Family Member:        Relationship: _____________ 
 
PART 2:SOCIO-DEMOGRAPHIC DATA 
Date of Birth:                                                            
                                
                         Date       Month          Year 
             
Age:              years  
 
Sex:                       Male            Female          
 
Height:         cms 
 
 
Weight:                      Kg                         
Educational status: What is the highest level of education you have completed? 
1  Illiterate                           2  Primary school (class I-V) 
3  High school (class VI-IX)    4  Class X completed 
5  Class X                                 6  Diploma/Bachelor’s degree 
7  Master’s degree                    8  Professional or doctoral degree 
9  Other: ___________________________ 
 
Occupation:                                                                                             Work Address: 
1  Professional (eg. Lawyer, accountant, nurse) 
2  Skilled worker (eg. Carpenter, computer operator) 
3  Clerical/Shop Owner/ Farm Owner  
4  Unskilled worker/manual labor (eg. Driver, sweeper) 
5  Retired/pensioner 
6  Unemployed 
7  Other: ___________________________________ 
9  do not want to respond 
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                                                                      Date        Month           year 
         
Average monthly income of entire family 
1  < Rs.5000 
2  Rs 5000 – 10,000 
3  Rs 10,001 – 20, 000                                                                                                                                                                
4  Rs 20, 001 – 30,000                                                                                                                                                      
5  > Rs 30,000                                                                                                                                                   
9  do not want to respond 
Visit 1            Day 0 
INCLUSION CRITERIA 
S.No                     Criteria Yes N0 
1 The subject or parent/legal guardian if applicable has given 
written informed, dated consent 
  
2. Are 1 or more current sputum smears Positive? (1+ or greater)    
3. No Previous antituberculosis therapy   
4 Is the patient between 18 and 75 years of age?   
5 Patient with firm home address and are willing and able to 
comply with the study protocol 
  
          N.B: A ‘no’ response for questions 1 to 3 will result in exclusion 
      from the study. 
EXCLUSION CRITERIA 
S.No                                                           Criteria Yes No 
 1.  *Does the patient have a positive pregnancy test or is she currently lactating?   
2. Is the patient HIV positive?   
3. Does the patient have only extra pulmonary Tuberculosis?   
4. Is the Patient receiving steroids or cytotoxic drugs?   
5. Is the patient is in post transplant condition or having metastatic malignancy?   
Signature of clinical research officer --------------------------- 
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                                                                      Date        Month           year 
         
6. Is there any clinical or laboratory [i.e. INR or serum creatinine two times the upper 
limit of normal range] evidence of hepatic or renal disease?  
  
7. Does the patient have active diarrhea with steatorrhea for more than 15 days in the 
last 30 days? 
  
8. Is the patient expected to die within the period of ATT?   
 
*Women of Child Bearing Potential (WOCBP) include any female who has experienced menarche and who has not 
undergone successful surgical sterilization or is not post-menopausal. Even women who are using oral, implanted or inject 
able Contraceptive hormones or mechanical products (intrauterine devices, barrier methods) to Prevent pregnancy, who 
are practicing abstinence, or who have a partner that is sterile (e.g., vasectomy), should be considered to be of child 
bearing potential. 
N.B. A ‘yes’ response for questions 1 to 8 will result in exclusion of the 
study. 
VISIT 1           DAY 0 
 
Copy of the consent form given to the subject:  YES                  NO                                            
 
If no, specify why ------------------------------------------------------------------------------------ 
 
Child bearing potential 
 
a. If the subject is female, is she of child bearing potential? 
    
            Yes     
 
                   
                   No 
 
b. If yes, pregnancy test outcome 
 
                   Positive 
 
             Negative     
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
             CONTACT DETAILS OF DOTS PROVIDER CLOSE TO PATIENT 
ACCESS 
NAME OF THE DOTS PROVIDER: 
 
                               
ADDRESS: 
 
                               
                               
                               
MOBILE NO: 
 
          
 
LANDLINE NO: 
 
           
 
    
           
 Study Specimen Collection ON SCREENING VISIT 1 
 
 
1. Two Spot sputum specimen  collected visit day 1 
(minimum 4 ml, saliva to be rejected) in sterile 
labeled screw top container for Smear, Culture & 
Drug sensitivity Test: delivery date:  
 dd  /mm  /yy         Check if induced   
 
2. Urine sample from women collected and sent to 
Clinical Pathology lab  delivary date: 
dd  /mm  /yy   
3.Whole blood for Serum creatinine, albumin, SGPT, 
 
4. Whole Blood for HIV collected in red capped tube 
labeled and sent ICTC lab. 
      Delivery date: 
dd  /mm  /yy    
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
calcium, Vitamin D (25 OH), collected in a labeled plain 
tube and sent to Clinical Biochemistry Lab ).  
      Delivery date: 
dd  /mm  /yy    
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
VISIT I: ICTC 
Have you ever had a HIV test before?     1  yes 2  no 
If tested, date of most recent HIV test:   mm  /yy    
Result:   1  positive      2  negative     3  don’t want to answer 
Where was the previous HIV test performed? 1 CMC- Virology    2 CMC - VCTC    3 CHAD     4 Other, Specify 
___________________________________________________________ 
 
If the patient has a written result of HIV testing (negative within the last one month, positive ever), repeat ICTC can be 
avoided.  A photocopy of the HIV result must be attached to the CRF.  The study prefers ICTC testing since the cost is lower 
and counseling is included. 
 
If HIV positive, is patient on ART?                1  yes 2  no 
Most recent CD4 count and date ____________________________  Previous CD4 and date 
___________________________ 
Viral load if available and date _____________________________   Previous viral load and date 
________________________ 
Current ART treatment (drug, dose, date of initiation) 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
 
Previous ART treatment (drug, dose, date of initiation) 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
_____________________________________________________________________________________ 
 
 
Date of ICTC: 
dd  /mm  /yy   
ICTC counselor initials 
 
        _________________ 
 
2.ICTC result                                   1  positive      2  negative  
 
If ICTC result is not available, explain 
why___________________________________________ 
___________________________________________________________________________
_    
 
If HIV positive, send and record current CD4 Count     ______________  (study will pay for 
this) 
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VISIT 1: Radiology 
 
1.  Previous 
CXR 
available? 
  1  yes 
  2  no 
  9  unknown 
 
Previous CXR 
result is 
acceptable, only if 
it was requested as 
part of the workup 
of the current 
illness.  
Radiologist’s 
interpretation is 
required for the 
study. 
2. Previous CXR  Date:  
dd  /mm  /yy   
 
3. Previous CXR Result: 
 1  normal                      5  needs further review 
 2  cavitary             9  unknown  
 3  non-cavitary: consistent w/ TB  
 4  non-cavitary: NOT consistent w/TB 
 
Record exact radiologist’s interpretation (or 
attach photocopy) 
______________________________________
______________________________________
______________________________________
_____________________ 
4. Study CXR Date:   
dd  /mm  /yy   
 
5. Study CXR Result:  
 1  normal 5  needs further 
review 
 2  cavitary  9  unknown  
 3  non-cavitary: consistent w/ TB  
 4  non-cavitary: NOT consistent w/TB 
 
Record exact radiologist’s interpretation (or 
attach photocopy) 
________________________________________
________________________________________
________________________________________
__________________ 
 
 
 
If CD4 available within the last 3 months, it can be used instead of sending a new test. 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
 
 
 
 
 
 
 
 
 
 
Visit 1        Day 0 
                                           
       SCREENING LABORATORY RESULT ELIGIBILITY CHECKLIST 
                                                                                             
                           Date form filled out                                                         Date Blood Drawn 
 
  
                      Date           Month               Year                                  Date          Month                Year 
 
 
TEST 
          
         RESULT 
 
LAB RESULT 
ELIGIBILITY 
MEETS 
ELIGIBILITY 
CRITERIA 
 
Serum Creatinine 
  
<1.5 mg/dl 
 
YES               NO 
 
Serum Calcium 
  
  mg/dl 
              
 
 
Serum Albumin 
 
 
 
   g/dl 
 
 
Serum SGPT     IU/L  
 
Corrected Serum 
Calcium 
  
For every   in 
albumin of  
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
1g/dl,calcium  by 
 0.7 mg/dl 
 
Urine Pregnancy 
Test 
  
Negative 
 
 
YES               NO 
 
HIV antibody  Negative Yes             No 
Vitamin D – 25  
OH Vitamin D3 
  
ng/ml 
 
 
           
 
 
 
 
 
 
VISIT 1              DAY 0 
Karnofsky Performance Index Tool 
 
Functional Definition Rating 
(%) 
Criteria 
Able to carry on normal 
activity and to work; no 
special care needed 
100 Normal no complaints; no evidence 
of disease 
90 Able to carry on normal activity; 
minor signs or symptoms of disease 
80 Normal activity with effort; some 
signs or symptoms of disease 
Unable to work; able to live 
at home and care for most 
personal needs; varying  
amount of assistance 
needed 
 
70 Cares for self; unable to carry on 
normal activity or to do active work 
60 Requires occasional assistance, but is 
able to care for most of his personal 
needs 
50 Requires considerable assistance 
frequent medical care 
Unable to care for self; 40 Disabled; requires special care and 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
requires equivalent of 
institutional or hospital 
care; disease may be 
progressing rapidly 
 
assistance 
30 Severely disabled; hospital admission 
is indicated although death not 
imminent 
20 Very sick; hospital admission 
necessary; active supportive 
treatment necessary 
10 Moribund; fatal processes 
progressing rapidly 
0 Dead 
 
Karnofsky Performance Index of the Subject: 
 
 
 
 
 
 
 
VISIT 1             DAY 0 
SIGNIFICANT MEDICAL HISTORY 
 
PRESENT PULMONARY TUBERCULOSIS 
 
 
Date of Diagnosis 
 
 
  
                  Date           Month                 Year 
 
 
Sputum Smear done at trial site: 
   
Smear 
Results 
                       Date  
Result 
 
   Reporting Lab 
 
Smear 1 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
 
Sputum 
Culture 
Results 
 
Method 
                      
                 Date 
 
 
Susceptibility 
 
 
   
Reporting       
       Lab 
 
Positive 
 
Yes 
 
No 
 
 
 
1. 
 
---------- 
 
 
2. 
 
---------- 
 
 
      
      Date         Month             Year 
 
 
 
      Date         Month             Year 
 
INH   
RIF  
Drug Sus 
 
 
 
 
 
 
 
PRESENT PULMONARY TUBERCULOSIS (contd) 
VISIT 1             DAY 0 
 
 
         Date           Month               Year 
Smear 
Results 
                       Date  
   Result 
 
Reporting Lab & 
Location 
Smear 1 
 
 
 
 
        Date           Month               Year 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
Sputum smears done outside trial site: 
 
Smear 3 
 
 
 
     Date        Month                    Year 
  
 
TREATMENT: 
 
 
CATEGORY 
 
 
                                 TREATMENT CHART 
 
CAT I 
 
 
 
CAT II 
 
 
 
CAT III 
 
 
 
 
 
DRUG 
 
 
DOSE 
 
INTERVAL 
 
DURATION 
 
DOSES 
MISSED 
 
 
 
 
   
 
 
    
 
 
    
 
 
    
 
 
 
VISIT 1          DAY 0 
 
Category of Pulmonary Tuberculosis: 
 
 
SN
o 
                             
                         Category 
 
1 New 
Smear 2 
 
 
        Date         Month                    Year 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
2 Transferred in 
 
3 Relapse 
 
4 Failure 
 
5 Treatment after default 
 
6 Others(Specify) 
 
----------------------------------------------------------------------------------------------------
---------------- 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
VISIT 1             DAY 0 
PREVIOUS TUBERCULOSIS: 
 
 
Status 
 
 
Pulmonary              Extra pulmonary                   No 
 
Date of Diagnosis 
 
 
 
                 Date          Month               Year 
 
How Diagnosed? 
 
 
   
Sputum 
Culture 
Results 
 
Method 
                      
                 Date 
 
 
Susceptibility 
 
 
   
Reporting       
       Lab 
 
Positive 
 
Yes 
 
No 
1. 
 
---------- 
 
 
2. 
 
 
      
      Date         Month             Year 
 
 
 
INH   
RIF  
Drug Sus 
 
Smear 
Results 
               Date  
Result 
 
   Reporting Lab 
Smear 1 
 
 
 
 
        Date           Month               Year 
  
 
Smear 2 
 
 
 
            Date         Month                    Year 
  
 
Smear 3 
 
 
 
         Date        Month                   Year 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
 
 
 
---------- 
 
      Date         Month             Year 
VISIT 1             DAY 0 
PREVIOUS TUBERCULOSIS {contd} 
 
CHEST X RAY INTERPRETATION: 
 
TEST 
 
 
                           DATE 
 
            REPORT 
 
CXR 1 
 
 
 
           Date         Month              Year 
 
 
CXR 2 
 
 
 
            Date         Month               Year 
 
 
TREATMENT: 
 
 
CATEGORY 
 
                                 TREATMENT CHART 
 
CAT I 
 
 
 
CAT II 
 
 
 
CAT III 
 
 
 
Date of Treatment: 
                                                 
 To 
 
    Date          Month             Year                      Date        Month               Year 
 
DRUG 
 
 
DOSE 
 
INTERVAL 
 
DURATION 
 
DOSES 
MISSED 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
 
    
 
RNTCP 
Outcome? 
Cured                    Completed Treatment                Failure              
Defaulted              Transferred out 
                              
PREVIOUS PULMONARY TUBERCULOSIS (Contd) 
 
Sputum smears done outside trial site: 
 
 
 
 
 
 
 
 
 
 
 
Smear 
Results 
                       Date  
   Result 
 
Reporting Lab & 
Location 
Smear 1 
 
 
 
 
        Date           Month               Year 
  
 
Smear 2 
 
 
 
        Date         Month                       Year 
  
 
Smear 3 
 
 
 
    Date          Month                   Year 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
 
 
 
 
 
 
                             
  VISIT 1             DAY 0 
 
HISTORY OF RESPIRATORY DISEASE: 
 
 
DISEASE 
 
 
PAST 
 
PRESENT 
PERTINANT DETAILS 
INCLUDE SURGICAL 
PROCEDURE 
AND CURRENT 
TREATMENT 
 
 
Disease 1: 
 
-------------------------------------- 
   
 
 
Disease 2: 
 
------------------------------------- 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
Disease 3: 
 
-------------------------------------- 
 
 
   
 
                              
 
 
 
VISIT 1             DAY 0 
 
HISTORY OF CARDIOVASCULAR DISEASE 
 
 
DISEASE 
 
 
PAST 
 
PRESENT 
PERTINANT DETAILS 
INCLUDE SURGICAL 
PROCEDURE 
AND CURRENT 
TREATMENT 
 
 
Disease 1: 
 
-------------------------------------- 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
Disease 2: 
 
------------------------------------- 
 
 
 
 
 
Disease 3: 
 
-------------------------------------- 
 
 
 
   
 
VISIT 1             DAY 0 
 
HISTORY OF GASTROINTESTINAL OR LIVER DISEASE 
 
 
DISEASE 
 
 
PAST 
 
PRESENT 
PERTINANT DETAILS 
INCLUDE SURGICAL 
PROCEDURE 
AND CURRENT 
TREATMENT 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
 
Disease 1: 
 
-------------------------------------- 
   
 
 
Disease 2: 
 
------------------------------------- 
 
 
 
   
 
 
Disease 3: 
 
-------------------------------------- 
 
 
   
 
VISIT 1             DAY 0 
 
HISTORY OF ENDOCRINE DISORDERS 
 
 
DISEASE 
 
PAST 
 
PRESENT 
PERTINANT DETAILS 
INCLUDE SURGICAL 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 PROCEDURE 
AND CURRENT 
TREATMENT 
 
 
Disease 1: 
 
-------------------------------------- 
   
 
 
Disease 2: 
 
------------------------------------- 
 
 
 
   
 
 
Disease 3: 
 
-------------------------------------- 
 
   
 
VISIT 1             DAY 0 
 
HISTORY OF HAEMATOLOGICAL DISEASE 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
DISEASE 
 
 
PAST 
 
PRESENT 
PERTINANT DETAILS 
INCLUDE SURGICAL 
PROCEDURE 
AND CURRENT 
TREATMENT 
 
 
Disease 1: 
 
-------------------------------------- 
   
 
 
Disease 2: 
 
------------------------------------- 
 
 
 
   
 
 
Disease 3: 
 
-------------------------------------- 
 
 
   
 
VISIT 1             DAY 0 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
HISTORY OF NEUROLOGICAL DISEASE 
 
 
DISEASE 
 
 
PAST 
 
PRESENT 
PERTINANT DETAILS 
INCLUDE SURGICAL 
PROCEDURE 
AND CURRENT 
TREATMENT 
 
 
Disease 1: 
 
-------------------------------------- 
   
 
 
Disease 2: 
 
------------------------------------- 
 
 
 
   
 
 
Disease 3: 
 
-------------------------------------- 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
 
 
 
VISIT 1             DAY 0 
 
HISTORY OF ALLERGY 
 
 
ALLERGY 
TO 
 
 
         DATE OF REACTION 
 
   TYPE OF REACTION 
DRUG 1 
____________ 
 
 
 
      Date         Month              Year 
 
DRUG 2 
____________ 
 
 
      Date         Month              Year 
 
DRUG 3 
____________ 
 
 
      Date          Month             Year 
 
DRUG 4 
____________ 
 
 
     Date           Month             Year 
 
DRUG 5 
____________ 
 
 
      Date         Month              Year 
 
 
 
        
        
        
        
        
Signature of clinical research officer --------------------------- 
Author: Dr. Peter Daley                                                                             Page 25 of 54 
                                                                                                                     
 
Vitamin D Randomized Controlled Trial Case Report Form Version 2 1st Nov 2009 
                                  Mathai D, Daley P, John KR,  Jayaseelan L, Christopher DJ, Micheal JS, Joel N,  Arun JoseN 
 
 
STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
VISIT 1             DAY 0 
 
Current Drug Sheet 
 
 
 
Generic 
Name of the 
Drug 
Dose/Route/ 
Interval 
             Start Date 
 
   Date     Month         Year 
 
1 
   
 
 
 
2 
 
   
 
3 
 
   
 
4 
 
   
 
 
5 
   
 
 
6 
   
 
7 
 
   
 
 
8 
   
 
9 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
10 
 
                                             
Signature of clinical research officer --------------------------- 
Author: Dr. Peter Daley                                                                             Page 28 of 54 
                                                                                                                     
 
Vitamin D Randomized Controlled Trial Case Report Form Version 2 1st Nov 2009 
                                  Mathai D, Daley P, John KR,  Jayaseelan L, Christopher DJ, Micheal JS, Joel N,  Arun JoseN 
 
 
STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
VISIT 1             DAY 0 
 
HABITS  
 
TYPE OF  
HABITS 
 
PAST 
 
PRESENT 
 
NO 
 
        DETAILS  
 
 
SMOKING 
 
 
    
 
QUESTION    ANSWER 
Cigarettes/day  
Year Started  
Year Stopped  
Years smoking  
 
 
BETEL NUTS 
 
 
 
 
    
 
QUESTION    ANSWER 
Quids/day  
Year Started  
Year Stopped  
Years Chewing  
 
 
ALCOHOL 
 
 
 
 
    
 
QUESTION    ANSWER 
Ounces/day  
Year Started  
Year Stopped  
Years Drinking  
 
If Included, Patient randomized to receive treatment bottle number: 
 
 
Signature of Trial Coordinator offer visit 1              Signature of Investigator offer visit 1 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
---------------------------                                               ------------------------ 
 
 
VISIT 2              Day 2 
 
Informed Consent signed or thumb printed and stored at IDTRC in locked 
cupboard 
 
        [1] Yes               
                                                                                       
        [2] No 
                                                                         
ATT:   
 
First dose of ATT provided as required?       
 
        [1] Yes               
                                                                                       
        [2] No 
                                                                         
               If no, reason ---------------------------------------------------------------------------- 
 
Study drug dose 1 given directly observed: 
 
Yes 
 
No 
 
If no, reason -------------------------------------------------------------------------------------- 
 
  
Visit 3                   Day 4 
ATT:   
 ATT doses provided as required?        
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
Have there been any adverse events since last visit?    
                    
                  [1] Yes 
 
            
                  [2] No 
 
 * If yes fill the details in adverse events report form 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
Visit 6            Day 16 
ATT:   
ATT doses provided as required? 
 
                          [1] Yes       
 
                           [2] No 
                                                                         
If no, how many doses missed?               
 
Reason: ------------------------------------------------------------------------------------------------- 
Trial drug: 
Second dose of trial drug provided directly observed? 
 
   [1] Yes          
 
                       [2] No  
      If no, 
Reason: ------------------------------------------------------------------------------------------------- 
Adverse events: 
Have there been any adverse events since last visit?    
 
                   [1] Yes * 
 
                   [2] No 
 
*if yes, fill the details in adverse event form 
 
1. Spot sputum specimen 1 collected Visit 6 (minimum 4 ml, saliva to be rejected) if 
patient can produce, in sterile labeled screw top container for culture  
      delivery date:  
 dd  /mm  /yy                 Check if induced   
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
                                                                                                 Signature----------------- 
                                            
 
VISIT 7                  Day 30 
ATT:   
 
ATT doses provided as required? 
 
                          [1] Yes       
                                                                     
                           [2] No 
                                                                         
If no, how many doses missed?               
 
Reason: ------------------------------------------------------------------------------------------------ 
 
Trial drug: 
 
Third dose of trial drug provided directly observed?    
 
   [1] Yes          
 
                       [2] No  
      
 If no,  
 Reason: ------------------------------------------------------------------------------------------------ 
 
Adverse events: 
 
 Have there been any adverse events since last visit?    
 
                   [1] Yes * 
                  
                    [2] No 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 * If yes fill the details in adverse events report form 
 
 
 
 
2. Spot sputum specimen 1 collected Visit 7 (minimum 4 ml, saliva to be rejected) if 
patient can produce, in sterile labeled screw top container for Culture & Smear 
delivery date:  
 dd  /mm  /yy                 Check if induced   
 
Blood for calcium testing collected: 
 
 
Yes  
 
No 
 
 
If no, reason -------------------------------------------------------------------------------------- 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
 
 
 
 
 
Visit 8          Day 44 
ATT:   
ATT doses provided as required? 
 
                          [1] Yes       
 
                           [2] No 
                                                                         
If no, how many doses missed?               
 
Reason: ------------------------------------------------------------------------------------------------- 
Trial drug: 
Fourth dose of trial drug provided directly observed? 
 
   [1] Yes          
 
                       [2] No  
      
 If no, how many doses missed?             
  
Reason: ------------------------------------------------------------------------------------------------- 
Adverse events: 
Have there been any adverse events since last visit?    
 
                   [1] Yes *                               [2] 
 
*if yes, fill the details in adverse event form 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
3. Spot sputum specimen 1 collected study visit 8 (minimum 4 ml, saliva to be rejected) 
if patient can produce, in sterile labeled screw top container for culture.delivery date:  
 dd  /mm  /yy                 Check if induced   
 
Signature---------- 
 
 
 
 
Visit 9           Day 58     END OF INTENSIVE PHASE 
ATT:   
ATT doses provided as required? 
 
                          [1] Yes       
 
                           [2] No 
                                                                         
If no, how many doses missed?               
 
Reason: ------------------------------------------------------------------------------------------------- 
 
ATT Compliance: 
  
How many doses of ATT taken   in the intensive phase                        
 
 
How many doses of ATT missed in the intensive phase?                      
 
Trial Drug compliance: 
 
 4 doses received  
 
If not, how many doses missed?                               Doses Missed      Reason 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
                                                                   Dose1 [day 2] -------------------------------------- 
        
                                                                   
                                                                   Dose 2 [day16] -------------------------------------                
 
                                                                   Dose 3 [day 30] ------------------------------------- 
                                      
                                                                     
                                                                   Dose 4 [day 44] -------------------------------------          
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
VISIT 9      DAY 58 
Adverse events: 
Have there been any adverse events since last visit?    
 
                   [1] Yes * 
 
 
                   [2] No 
 
*if yes, fill the details in adverse event form 
4. Spot sputum specimen 1 collected study visit 9 (minimum 4 ml, saliva to be rejected) 
if patient can produce, in sterile labeled screw top container for culture (to be repeated 
only if last culture positive) delivery date:  
 dd  /mm  /yy                 Check if induced   
Karnofsky Performance index of the subject: 
 
% 
 
Weight of the Subject:                   
 
Kg 
 
                      Sputum smears done outside trial site(End of Intensive Phase)                                                                                                    
   
   
Smear 
Results 
                       Date  
   Result 
 
Reporting Lab & 
Location 
Smear 1 
 
 
 
 
        Date       Month               Year 
  
 
Smear 2 
 
 
 
        Date      Month                 
Year 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
 
Sputum smears done outside trial site (end of two months continuation period) 
 
Sputum smears done outside trial site (end treatment period) 
 
Smear 3 
 
 
       Date       Month                 
Year 
Smear 
Results 
                       Date  
   Result 
 
Reporting Lab & 
Location 
Smear 1 
 
 
 
 
        Date           Month          Year 
  
 
Smear 2 
 
 
 
        Date       Month             Year 
  
 
Smear 3 
 
 
 
      Date        Month               Year 
  
Smear 
Results 
                       Date  
   Result 
 
Reporting Lab & 
Location 
Smear 1 
 
 
 
 
     Date         Month                Year 
  
 
Smear 2 
 
 
 
      Date         Month               Year 
  
 
Smear 3 
 
 
 
      Date        Month               Year 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
                                              
 
 
 
 
 
 
Concomitant drug sheet [Day 58] 
 
 
SNo 
 
 
Generic  
Name of the 
Drug 
 
Dose/Route/ 
Interval 
 
             Start Date 
 
   Date      Month          Year 
 
On 
going                           
 
1 
   
 
 
 
 
2 
 
    
 
3 
 
    
 
4 
 
    
 
 
5 
    
 
 
6 
    
 
7 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
8 
 
9 
 
    
 
10 
 
    
                                
 
VISIT 10        Day 182         FINAL VISIT 
 
ATT:   
 
Doses provided as required?      
 
                          [1] Yes       
                                                                      Weight  
                           [2] No 
                                                                         
If no, how many doses missed?                 
 
Reason: ----------------------------------------------------------------------------------------- 
 
Adverse events: 
  
Have there been any adverse events since last visit?    
 
                   [1] Yes * 
 
                   [2] No 
 
 
• If yes fill the details in adverse events report form 
•  
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
2. Spot or morning sputum specimen 1 collected on study visit 10 (minimum 4 ml, 
saliva to be rejected) if patient can produce, in nonsterile labeled screw top 
container for Culture delivery date:  
 dd  /mm  /yy                 Check if induced   
•  
 
 
 
 
 
VISIT 10             DAY 180 
 
Blood sample collected for Vitamin D testing:  
 
Yes                         
 
 No 
 
If no, reason------------------------------------------------------------------------------------------ 
 
Outcome of RNTCP: 
 
                                             Cured  
                                                                  
Default  
                               
                                    Failure  
                                     
Treatment completed 
                                       
                                                 Died  
 
                                              Transferred Out  
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
Here are the RNTCP treatment outcome definitions: 
 
Cured   : Smear positive that becomes smear negative during last month of 
treatment and at least once prior. 
 
Complete  : Completed treatment but not cured or failed 
 
Died   : Any reason during treatment 
 
Failed   : Smear positive interrupted for two consecutive months or more 
 
Transferred out: Transferred to a new reporting unit and outcome unknown. 
 
 
Protocol violations 
 
 
SNo 
  
Date [dd/mm/yy] 
 
   Visit       
 Number 
 
    Type of    
   violation             
 
      Reason 
 
 
 
  __ __/__ __ /__ __ 
   
 
    
 
 __ __/__ __ /__ __ 
   
  
__ __/__ __ /__ __ 
   
  
__ __/__ __ /__ __ 
   
  
__ __/__ __ /__ __ 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
 
                                      
HYPERCALCAEMIA REPORT 
                         
ADVERSE EVENT                               SERIOUS ADVERSE EVENT                          
                                                                     [Complete the SAE form] 
 
  
__ __/__ __ /__ __ 
   
  
__ __/__ __ /__ __ 
   
  
 __ __/__ __ /__ __ 
   
  
__ __/__ __ /__ __ 
   
  
__ __/__ __ /__ __ 
   
  
 __ __/__ __ /__ __ 
   
  
__ __/__ __ /__ __ 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
Hypercalcemia :                       Symptomatic                                                                    Asymptomatic      
                                                                         
                                                 Serum calcium >13.9mg/dl :                        Yes                                  No                    
  
                                                 Serum calcium 10.4 to 13.9mg/dl :               Yes                                  No 
 
 
 
SNo   
    
 
SYMPTOMS OF HYPERCALCEMIA                       
          
             DATE OF ONSET 
 
      Date       Month          Year 
 
1 
 
  
 
2 
 
  
 
3 
 
  
 
4 
 
  
 
5 
 
  
 
Tested as part of protocol 
 
Tested outside of protocol 
 
Severity                      Mild                    Moderate                    Severe  
Hypercalcemia report {Contd} 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
HYPERCALCEMIA TREATMENT SHEET 
 
Specific treatment given:            [1] Yes          
 
                                                                                   
                                                       [2] No          
 
Hospital admission needed?       [1] Yes          
 
                                                                                   
                                                       [2] No          
 
                         
If Yes, Date Admitted: 
 
 
Date Discharged             : 
 
Out come of treatment                     [1] improved              
 
                                                           [2] Cured                   
 
                                                           [3] Worsened            
 
Treatment details:   ----------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------ 
                                                                                                       
------------------------, 
Signature of the Physician treating. 
Hypercalcemia report {Contd} 
Study treatment consequence: 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
Action:                    
                    No action                                     
Subject:                                       
                    Withdrawn from the study                                               
     
Treatment given   
[Specify in concomitant treatment sheet]                                                                                          
                                         
Complete the following section at the time the event resolves or at the end of study, In the 
investigator’s judgement, was the study treatment the most likely cause of the 
hypercalcaemia? 
 
Yes                         
 
No  
 
* If no what was the most likely cause of the hypercalcaemia    
                                        
    [1] Disease under study 
 
[2] Other illness [specify]  
                  _________________________________ 
                                       
[3] Concomitant treatment –Drug or Non drug         
                  _____________________________ 
 
[4] Others [specify] 
                  __________________________________ 
       Does this AE quantify as an SAE                                                                                                   
 
                  YES         
                  
                   NO        
                                                                                                                                                                                                                                                
         ---------------------- 
Signature of clinical research officer --------------------------- 
Author: Dr. Peter Daley                                                                             Page 49 of 54 
                                                                                                                     
 
Vitamin D Randomized Controlled Trial Case Report Form Version 2 1st Nov 2009 
                                  Mathai D, Daley P, John KR,  Jayaseelan L, Christopher DJ, Micheal JS, Joel N,  Arun JoseN 
 
 
STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
                                                                                                 Investigator’s signature 
                                                           
                 Adverse events [others] 
 
 
N
O 
 
 Adverse event  
Severity 
1=mild 
2=moderate 
3=severe  
 
     Start date  
 
      Stop date  
   
Ongoing  
 
 Treatment  
  
 
 
 
 
 
  
__ __/__ __ /__ __ 
 
__ __/__ __ /__ __ 
 
 
 
 
  
 
 
 
 
 
  
__ __/__ __ /__ __ 
 
__ __/__ __ /__ __ 
 
   
 
  
 
 
 
 
 
  
__ __/__ __ /__ __ 
 
__ __/__ __ /__ __ 
 
 
 
 
  
 
 
 
 
 
  
__ __/__ __ /__ __ 
 
__ __/__ __ /__ __ 
 
 
 
  
 
 
  
__ __/__ __ /__ __ 
 
__ __/__ __ /__ __ 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
 
 
Signature 
Adverse events [others] {contd.} 
 
 
n
o 
 
 Adverse event  
Severity 
1=mild 
2=moderate 
3=severe 
 
     Start date  
 
      Stop date  
   
     
Ongoing  
 
  Treatment  
  
 
 
 
 
 
  
__ __/__ __ /__ __ 
 
__ __/__ __ /__ __ 
 
 
 
 
  
 
 
 
 
 
  
__ __/__ __ /__ __ 
 
__ __/__ __ /__ __ 
 
   
 
  
 
 
 
 
 
  
__ __/__ __ /__ __ 
 
__ __/__ __ /__ __ 
 
 
 
 
  
 
 
 
 
 
  
__ __/__ __ /__ __ 
 
__ __/__ __ /__ __ 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
  
 
 
 
 
  
__ __/__ __ /__ __ 
 
__ __/__ __ /__ __ 
 
     
 
 
Signature 
 
 
Record on Retrival Action 
 
 
SNo            Date of Missed Visit  
 
       Date         Month               Year 
Reason for 
missed visit 
  Contact      
   method 
Changes made to prevent 
further missed visit 
Outcome of 
retrieval 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
 
 
 
 
 
Appendix: Visit Schedule 
 
1 
 
     
 
 
2 
 
     
 
 
3 
 
     
 
 
4 
 
     
 
 
5 
 
     
 
6 
 
     
 
7 
 
     
 
8 
 
     
 
 
9 
     
Study periods and 
extension 
Screening TB Treatment 
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STUDY NUMBER             SITE NUMBER         DATE OF VISIT   
                                                                      Date        Month           year 
         
                                       
Clinical visit number V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 
Study Participation 
Day 
0 2 4 6 9 16 30 44 58 182 
TB Treatment Day -2 0 2 4 7 14 28 42 56 180 
Demographics *          
Informed consent * *         
Inclusion/exclusion 
criteria 
*          
Medical history *          
Screening Physical 
Exam 
*          
Karnofsky 
Performance Index 
*        *  
HIV *          
Serum creatinine *          
Pregnancy testing  Only if child 
bearing 
potential 
         
Serum albumin *          
Serum SGPT *          
Serum calcium *  *     *    
Chest X-ray *          
Sputum smears(if 
sputum available, using 
induction as necessary) 
 
* 
          
Sputum culture(if 
sputum available, using 
induction as necessary) 
 
* 
    * * * * ( to be repeated at day 
90 and 150 if positive at 
day 56) 
* 
Sputum  DST  *          
Vitamin D level  *        * 
           
Anti-TB Therapy   * * * * * * * * * 
Trial drug 
administration  
(Vitamin D or placebo) 
  *    *  *  *    
Adverse events 
recording 
   * * * * * * * * 
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Appendix 6 
Case Report Form Lab 
BASE LINE LABORATORY SCREENING RESULT 
CLINICAL BIOCHEMISTRY REPORT 
VISIT 1 
 
SIT 1Identification Details 
 
1. STUDY NUMBER _______________  
 
Date Blood sample received    Research officer entering the report ---------------- 
 
  
 
 
TEST 
   
RESULT 
   
DATE OF REPORT 
 
Serum Creatinine 
 
  
 
Serum Calcium 
 
      
 
Serum Albumin 
 
  
 
Serum SGPT 
 
  
 
Corrected Serum 
Calcium 
 
  
 
Urine Pregnancy 
 
  
 
Vitamin D – 25  
OH Vitamin D3 
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SIT 1Identification Details 
 
1. STUDY NUMBER*_______________  
 
SERUM CALCIUM REPORT ON FOLLOWUPS 
 
 
 
 
TEST 
 
VISIT NUMBER & 
DATE BLOOD 
SAMPLE RECEIVED 
 
 
RESULT 
 
DATE OF REPORT 
 
 
Sr. Calcium 
 
 
VISIT 3: 
 
  /mm  /yy   
 
  
  /mm  /yy   
 
 
Sr. Calcium 
 
 
VISIT 7: 
 
  /mm  /yy   
 
  
  /mm  /yy   
 
 
 
 
Vitamin D – 25  
OH Vitamin 
D3 
 
 
Visit 10 
 
  /mm  /yy   
 
 
 
  
  /mm  /yy   
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CLINICAL MICROBIOLOGY - LABORATORY  CASE REPORT FORM 
VISIT 1 
 
Identification Details 
Study No: _________________________ 
 
 
Day 0 - Sputum Liquid Culture Results 
 
 
1. Date specimen received in 
laboratory: 
                  dd  /mm  /yy   
 
 
2. Date culture inoculated: 
                dd  /mm  /yy   
3. Date Culture Inoculated: 
     dd   /mm  /yy   
 
 
 
 
4. Research officer performing NALC/NaOH  __________               
 
5. Research Officer inoculating Culture _______________ 
 
6. Results of culture (circle one)    
           
• Positive                   
• Negative at 42 days             
• Contaminated 
 
 Days from inoculation until positive ___________________    
                                                                       
 
If contaminated, actions taken ________________________________________________ 
Reinoculation date     dd   /mm  /yy   
Results of reinoculation culture (circle one) 
 
Positive                       Negative at 42 days                               Contaminated 
 
Days from reinoculation until positive ____________ 
 
Date of reading Growth Index 
  
  
  
  
  
CLINICAL MICROBIOLOGY - LABORATORY  CASE REPORT FORM 
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VISIT 1 
 
Identification Details 
Study No: _________________________ 
 
 
Day 0: Sputum Susceptibility Report 
 
Sputum 
Culture 
Results 
 
Method 
                      
                 Date 
 
 Susceptibility 
 
 
Positive 
 
Yes 
 
No 
 
 
 
 
 
 
Date of Inoculation: 
 
 
      
      Date         Month             Year 
Date of Reading: 
 
 
 
      Date         Month             Year 
 
INH   
RIF  
Drug Susceptibility 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL MICROBIOLOGY - LABORATORY  CASE REPORT FORM 
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VISIT 6 
 
Identification Details 
Study No: _________________________ 
 
 
Day 16 - Sputum Liquid Culture Results 
 
 
7. Date specimen received in 
laboratory: 
                  dd  /mm  /yy   
 
 
8. Date culture inoculated: 
                dd  /mm  /yy   
9. Date Culture Inoculated: 
     dd   /mm  /yy   
 
 
 
 
10. Research officer performing NALC/NaOH  __________               
 
11. Research Officer inoculating Culture _______________ 
 
12. Results of culture (circle one)    
           
• Positive                   
• Negative at 42 days             
• Contaminated 
 
 Days from inoculation until positive ___________________    
                                                                       
 
If contaminated, actions taken ________________________________________________ 
Reinoculation date     dd   /mm  /yy   
Results of reinoculation culture (circle one) 
 
Positive                       Negative at 42 days                               Contaminated 
 
Days from reinoculation until positive ____________ 
 
Date of reading Growth Index 
  
  
  
  
  
 
CLINICAL MICROBIOLOGY - LABORATORY  CASE REPORT FORM 
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VISIT 7 
 
Identification Details 
Study No: _________________________ 
 
 
Day 30 - Sputum Liquid Culture Results 
 
 
13. Date specimen received in 
laboratory: 
                  dd  /mm  /yy   
 
 
14. Date culture inoculated: 
                dd  /mm  /yy   
15. Date Culture Inoculated: 
     dd   /mm  /yy   
 
 
 
 
16. Research officer performing NALC/NaOH  __________               
 
17. Research Officer inoculating Culture _______________ 
 
18. Results of culture (circle one)    
           
• Positive                   
• Negative at 42 days             
• Contaminated 
 
 Days from inoculation until positive ___________________    
                                                                       
 
If contaminated, actions taken ________________________________________________ 
Reinoculation date     dd   /mm  /yy   
Results of reinoculation culture (circle one) 
 
Positive                       Negative at 42 days                               Contaminated 
 
Days from reinoculation until positive ____________ 
 
Date of reading Growth Index 
  
  
  
  
CLINICAL MICROBIOLOGY - LABORATORY  CASE REPORT FORM 
VISIT 8 
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Identification Details 
Study No: _________________________ 
 
 
Day 44 - Sputum Liquid Culture Results 
 
 
19. Date specimen received in 
laboratory: 
                  dd  /mm  /yy   
 
 
20. Date culture inoculated: 
                dd  /mm  /yy   
21. Date Culture Inoculated: 
     dd   /mm  /yy   
 
 
 
 
22. Research officer performing NALC/NaOH  __________               
 
23. Research Officer inoculating Culture _______________ 
 
24. Results of culture (circle one)    
           
• Positive                   
• Negative at 42 days             
• Contaminated 
 
 Days from inoculation until positive ___________________    
                                                                       
 
If contaminated, actions taken ________________________________________________ 
Reinoculation date     dd   /mm  /yy   
Results of reinoculation culture (circle one) 
 
Positive                       Negative at 42 days                               Contaminated 
 
Days from reinoculation until positive ____________ 
 
Date of reading Growth Index 
  
  
  
  
 
 
CLINICAL MICROBIOLOGY - LABORATORY  CASE REPORT FORM 
VISIT 9 
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Identification Details 
Study No: _________________________ 
 
 
Day 56 - Sputum Liquid Culture Results 
 
 
25. Date specimen received in 
laboratory: 
                  dd  /mm  /yy   
 
 
26. Date culture inoculated: 
                dd  /mm  /yy   
27. Date Culture Inoculated: 
     dd   /mm  /yy   
 
 
 
 
28. Research officer performing NALC/NaOH  __________               
 
29. Research Officer inoculating Culture _______________ 
 
30. Results of culture (circle one)    
           
• Positive                   
• Negative at 42 days             
• Contaminated 
 
 Days from inoculation until positive ___________________    
                                                                       
 
If contaminated, actions taken ________________________________________________ 
Reinoculation date     dd   /mm  /yy   
Results of reinoculation culture (circle one) 
 
Positive                       Negative at 42 days                               Contaminated 
 
Days from reinoculation until positive ____________ 
 
Date of reading Growth Index 
  
  
  
 
CLINICAL MICROBIOLOGY - LABORATORY  CASE REPORT FORM 
VISIT 10 
 
Identification Details 
Study No: _________________________ 
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Day 182 - Sputum Liquid Culture Results 
 
 
31. Date specimen received in 
laboratory: 
                  dd  /mm  /yy   
 
 
32. Date culture inoculated: 
                dd  /mm  /yy   
33. Date Culture Inoculated: 
     dd   /mm  /yy   
 
 
 
 
34. Research officer performing NALC/NaOH  __________               
 
35. Research Officer inoculating Culture _______________ 
 
36. Results of culture (circle one)    
           
• Positive                   
• Negative at 42 days             
• Contaminated 
 
 Days from inoculation until positive ___________________    
                                                                       
 
If contaminated, actions taken ________________________________________________ 
Reinoculation date     dd   /mm  /yy   
Results of reinoculation culture (circle one) 
 
Positive                       Negative at 42 days                               Contaminated 
 
Days from reinoculation until positive ____________ 
 
Date of reading Growth Index 
  
  
  
  
 
CLINICAL MICROBIOLOGY - LABORATORY  CASE REPORT FORM 
Unscheduled Visits ( only if day 56 is Positive) 
 
Identification Details 
Study No: _________________________ 
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Day 90 - Sputum Liquid Culture Results 
 
 
37. Date specimen received in 
laboratory: 
                  dd  /mm  /yy   
 
 
38. Date culture inoculated: 
                dd  /mm  /yy   
39. Date Culture Inoculated: 
     dd   /mm  /yy   
 
 
 
 
40. Research officer performing NALC/NaOH  __________               
 
41. Research Officer inoculating Culture _______________ 
 
42. Results of culture (circle one)    
           
• Positive                   
• Negative at 42 days             
• Contaminated 
 
 Days from inoculation until positive ___________________    
                                                                       
 
If contaminated, actions taken ________________________________________________ 
Reinoculation date     dd   /mm  /yy   
Results of reinoculation culture (circle one) 
 
Positive                       Negative at 42 days                               Contaminated 
 
Days from reinoculation until positive ____________ 
 
Date of reading Growth Index 
  
  
  
  
 
CLINICAL MICROBIOLOGY - LABORATORY  CASE REPORT FORM 
Unscheduled Visit ( only if day 56 is positive) 
 
Identification Details 
Study No: _________________________ 
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Day 150 - Sputum Liquid Culture Results 
 
 
43. Date specimen received in 
laboratory: 
                  dd  /mm  /yy   
 
 
44. Date culture inoculated: 
                dd  /mm  /yy   
45. Date Culture Inoculated: 
     dd   /mm  /yy   
 
 
 
 
46. Research officer performing NALC/NaOH  __________               
 
47. Research Officer inoculating Culture _______________ 
 
48. Results of culture (circle one)    
           
• Positive                   
• Negative at 42 days             
• Contaminated 
 
 Days from inoculation until positive ___________________    
                                                                       
 
If contaminated, actions taken ________________________________________________ 
Reinoculation date     dd   /mm  /yy   
Results of reinoculation culture (circle one) 
 
Positive                       Negative at 42 days                               Contaminated 
 
Days from reinoculation until positive ____________ 
 
Date of reading Growth Index 
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